The proportion of CD86+ MDSCs in the spleen and blood after combination therapy was much higher than that in the tumor-bearing control group, and there was an increasing trend compared to the cryo-thermal therapy group (Figure 2E and Figure S3C). This evidence concerns the gene CD86 and neoplasm.